Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
11/2003
11/20/2003WO2003094890A1 Capsules for dry powder inhalers and methods of making and using same
11/20/2003WO2003094889A1 Lyophilization product
11/20/2003WO2003094888A1 Processes for forming a drug delivery device
11/20/2003WO2003094887A1 Sustained release formulation of protein and preparation method thereof
11/20/2003WO2003094886A2 Desmopressin in an orodispersible dosage form
11/20/2003WO2003094885A1 Sublingual pharmaceutical formulation of desmopressin
11/20/2003WO2003094884A1 Derivatised particulate inhalation carriers
11/20/2003WO2003094883A2 Process for the treatment of particles for use in pharmaceutical formulations
11/20/2003WO2003094850A2 Lipid a and other carbohydrate ligand analogs
11/20/2003WO2003094827A2 Dispersions of lipids for use as therapeutic and cosmetic agents and intracellular delivery vehicles
11/20/2003WO2003094812A1 Abuse-resistant opioid solid dosage form
11/20/2003WO2003094617A2 Use of vegf for treating bone defects
11/20/2003WO2003087180A3 New film coating
11/20/2003WO2003072016A3 Pharmaceutical compositions in particulate form
11/20/2003WO2003068145A3 Herbal immune system stimulant
11/20/2003WO2003066023A9 A stable pharmaceutical formulation comprising torsemide modification ii
11/20/2003WO2003059848A3 Hybrid immobilized catalytic system with controlled permeability
11/20/2003WO2003059331A3 Medicinal aerosol compositions with an amide and/or ester containing excipient compound
11/20/2003WO2003059317A3 Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient
11/20/2003WO2003055531A3 A hemostatic kit, a method of preparing a hemostatic agent and a method of promoting hemostasis
11/20/2003WO2003049719A3 Matrices for stabilizing and controlled release of problematic substances
11/20/2003WO2003045484B1 Open-celled substrates for drug delivery
11/20/2003WO2003041632A3 Eutectic-based self-nanoemulsified drug delivery system
11/20/2003WO2003040308A3 Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo
11/20/2003WO2003039465A3 Treating canker sores with patches to speed healing and relieve pain
11/20/2003WO2003024357A3 Microfabricated nanopore device for sustained release of therapeutic agent
11/20/2003WO2003020210A3 Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
11/20/2003WO2003018075A3 Transdermal therapeutic system with fentanyl or related substances
11/20/2003WO2003017972A8 Multi-component polymeric systems with reverse thermal gelation behaviour (e.g. peo-ppo copolymers)
11/20/2003WO2003009873A3 Use of pulmonary surfactant as humectant
11/20/2003WO2002100420A3 Pharmaceutical zeolite-based compositions containing zinc and erythromycin, to be used in the treatment of acne
11/20/2003WO2002089690A3 Dental composition for treating hypersensitive teeth
11/20/2003WO2002069906A3 Compounds and methods for the treatment of urogenital disorders
11/20/2003WO2002062368A8 Method of inducing a ctl response
11/20/2003WO2002053092A8 Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
11/20/2003WO2002051382A3 Ph-sensitive mucoadhesive film-forming gels and wax-film composites
11/20/2003WO2002041910A3 Methods and compositions for the treatment of diseases of the eye
11/20/2003WO2002032869A8 Substituted heterocyclic compounds for treating multidrug resistance
11/20/2003WO2002032407A3 Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis
11/20/2003WO2002028836A9 Novel crystalline forms of a factor xa inhibitor
11/20/2003WO2002026191A3 Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
11/20/2003WO2002002506A8 Compounds to treat alzheimer's disease
11/20/2003WO2002002505A8 Compounds to treat alzheimer's disease
11/20/2003US20030216714 Pump
11/20/2003US20030216589 Amino acids which deliver active agents to selected biological systems in increased or improved bioavailability
11/20/2003US20030216542 Modified insulin for delivery to lungs by breathing and treatment of diabetes
11/20/2003US20030216541 Systemic administration of a therapeutic preparation
11/20/2003US20030216475 Pharmaceutical composition
11/20/2003US20030216471 Retinoid formulations for aerosolization and inhalation
11/20/2003US20030216447 Compositions and method for treating infection in cattle and swine
11/20/2003US20030216443 Antidiabetic agents; using mixture of enzyme inhibitors
11/20/2003US20030216431 Antiinflammatory agents; vision defects; antiallergens; topical applying
11/20/2003US20030216420 Pharmaceutical composition for treating fecal incontinence and anal itch
11/20/2003US20030216418 Novel compositions comprising trimetrexate and methods of their synthesis and use
11/20/2003US20030216416 Novel crystalline of n-[4-[2-(2-amino-4,7-dihydro-4oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor
11/20/2003US20030216409 Heteroaryl alkyl piperazine derivatives
11/20/2003US20030216389 Therapeutic morpholino-substituted compounds
11/20/2003US20030216371 Synthetic catalytic free radical scavengers usefuyl as antioxidants for prevention and therapy of disease
11/20/2003US20030216365 Use of mometasone furoate for treating airway passage and lung diseases
11/20/2003US20030216353 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
11/20/2003US20030216352 Multicomponent complex for use with a substrate
11/20/2003US20030216333 Antisense modulation of glycogen synthase kinase3 alpha expression
11/20/2003US20030216331 Micelles
11/20/2003US20030216330 Especially for methicillin or vancomycin resistant Staphylococcus aureus, vancomycin resistant Enterococci or glycopeptide-intermediate Staphylococcus aureus
11/20/2003US20030216307 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
11/20/2003US20030216303 Emulsion preconcentrates containing cyclosporin or a macrolide
11/20/2003US20030216296 Amino acid sequences that mediate effective delivery of nucleic acids into cells and tissues, optionally using liposomes
11/20/2003US20030216287 N-(2-chlorophenyl) hydroxy- or alkoxyalkanamides, e.g.,N-(5-Chloro-2-hydroxyphenyl)-2-(2-hydroxyphenoxy)acetamid e); can deliver a broad range of active agents by various routes.
11/20/2003US20030215611 Film structures and methods of making film structures
11/20/2003US20030215585 Enrobed core
11/20/2003US20030215563 Coating a drug tablet, capsules, with a patterned film, multicoloring, transition line seams
11/20/2003US20030215550 Oligosaccharide for preventing natural pigment to discoloration; photostability, thermostability
11/20/2003US20030215533 Method of preventing respiratory infections
11/20/2003US20030215530 Tea extracts used for prophylaxis of alergies, atopic diseases or skin disorders
11/20/2003US20030215527 Novel substituted benzimidazole dosage forms and method of using same
11/20/2003US20030215525 Heat treated suspensions comprising group III compounds, preservatives, antideposit agents and optionally adjuvants, used for prophylaxis of gastrointestinal disorders
11/20/2003US20030215524 Stable pharmaceutical composition useful for treating gastrointestinal disorders
11/20/2003US20030215519 Preferential plugging of vascular sytems of mammals using microstructure particles comprising hydrolytically degradable crosslinked gels
11/20/2003US20030215518 Immediate release eplerenone compositions
11/20/2003US20030215516 Wet milling saturated solutions containing drugs such as steroids, while crystallizing to obtain microstructure particles in suspension
11/20/2003US20030215515 Preservation of bioactive materials by spray drying
11/20/2003US20030215514 Dispersible macromolecule compositions and methods for their preparation and use
11/20/2003US20030215513 Method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
11/20/2003US20030215512 Stable glassy state powder formulations
11/20/2003US20030215510 A delayed delivery drug dose to a fluid environment consists of a dose of drug, a second formulation with imbibes fluid and expands, a wall that confines both and permeable to the passage of fluid, a subcoat of hydroxyalkyl cellulose
11/20/2003US20030215509 Coated sustained release tablets of a hygroscopic compound for once-a-day therapy
11/20/2003US20030215508 Sustained release portion of unit dose containing guaifenesin, dextromethorphan and a release-delaying matrix contains a hydrophilic polymer and a water insoluble polymer, immediate release portion containing guaifenesin
11/20/2003US20030215507 Extended release formulation
11/20/2003US20030215506 Methods and compositions for enhancement of creatine transport
11/20/2003US20030215505 Rapidly disintegrating tablet for oral administration containing a compacted mixture of methylcellulose having specific viscosity and an edible calcium salt
11/20/2003US20030215504 Directly compressible acetaminophen compositions
11/20/2003US20030215503 Palatable chewable tablet
11/20/2003US20030215502 Fast dissolving dosage forms having reduced friability
11/20/2003US20030215501 An oral formulation containing from about 10% to 90% of a gel-forming polysaccharide derived from psyllium seed husk (containing xylose and arabinose)and 10% to about 90% of a fast dissolving excipient
11/20/2003US20030215500 Growing a powder material including a sugar alcohol or a saccharide as a main ingredient into a granulated material with a fixed particle diameter, mixing granulated material with a drug and a disintegrant, then compressing into a shape
11/20/2003US20030215499 As a binder a low amylose starch, which has been fully debranched using isoamylase; good binding and disintegration properties
11/20/2003US20030215498 Rapidly disintegrating comressed tablets comprising biologically active compounds
11/20/2003US20030215497 Adjuvant composition and methods for its use
11/20/2003US20030215496 Solid carrier includes a hydrophililc surfactant and a drug
11/20/2003US20030215495 Antihistamine formulations for soft capsule dosage forms
1 ... 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 ... 2991